EVMN
$25.03
Evommune, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneou...
Recent News
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade
Evommune has two autoimmune disorder treatments with blockbuster potential.
Evommune CEO Luis Peña Reveals What’s Behind Company’s Post-IPO Success
Evommune, Luis Peña Joins Ashley Mastronardi on NYSE Live to Reveal What’s Behind Company’s Post-IPO Success
Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m Placement
Evommune (EVMN) has drawn fresh attention after reporting statistically strong Phase 2a results for its eczema drug candidate EVO301, alongside a US$125.3m private placement arranged at US$27.88 per share. See our latest analysis for Evommune. The strong Phase 2a update and the US$125.3m private placement arrive as Evommune’s short term share price return has accelerated, with a 1 day move of 13.24% and a 7 day share price return of 82.38%, contributing to an 82.38% year to date share price...
Evommune’s stock rallies 70% on Phase IIa eczema data
The Phase IIa trial of EVO301 showed similar EASI reduction to Sanofi’s flagship AD drug Dupixent.
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill
Shares of Evommune nearly doubled on data suggesting it has a potential threat to Dupixent. Elsewhere, a closely watched narcolepsy drug got an FDA decision date and investors scrutinized Upstream’s asthma results.